SRZNW
Surrozen, Inc./DE
Key Financials
Operating Income
$-42092000
↓ 64.8%
Revenue
$3.5M
↓ 67.4%
Net Income
$-242026000
↓ 280.8%
Shareholders' Equity
$-187762000.00
↓ 778.2%
Cash & Equivalents
$89.2M
↑ 158.2%
EPS (Diluted)
$-32.37
↓ 49.4%
Total Assets
$98.7M
↑ 103.7%
Total Liabilities
$286.5M
↑ 310.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 10/2/2026 | View on SEC |
| SCHEDULE 13G | 10/1/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/11/2026 | View on SEC |
| 25-NSE | 8/7/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| SCHEDULE 13G/A | 7/24/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SRZNW |
| Company Name | Surrozen, Inc./DE |
| CIK | 1824893 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650-475-2820 |